(2) Asset impairment charges incurred in connection with the
rationalization of our worldwide manufacturing operations in order
to gain cost efficiencies and, to a lesser degree, the moderation of
the expansion of our R&D facilities.
(3) Accelerated depreciation resulting from our decision to accelerate
the closure of one of our ENBREL commercial bulk production
operations in connection with the rationalization of our worldwide
network of manufacturing facilities. The amount included above
represents the excess of accelerated depreciation expense over the
depreciation that would otherwise have been recorded if there were
no plans to accelerate the closure of this manufacturing operation.
(4) To exclude, from Other charges, loss accruals for leases
principally related to certain facilities that will not be used in
our business. Also, to exclude from SG&A in 2007, the cost
recoveries for certain restructuring expenses, principally with
respect to accelerated depreciation in connection with our
co-promotion agreement with Wyeth.
(f) To exclude loss accruals for settlements of certain commercial legal
(g) To exclude the loss accrual on the sale of certain less
significant marketed products and related assets.
(h) To exclude the write-off of inventory principally due to changing
regulatory and reimbursement environments.
(i) To exclude, for the applicable periods, merger related expenses
incurred due to the Alantos Pharmaceutical Holding, Inc. ("Alantos"),
Ilypsa, Inc. ("Ilypsa"), and Tularik Inc. acquisitions, primarily
related to incremental costs associated with retention. Substantially
all related amounts have been incurred.
(j) To exclude the non-cas
Copyright©2008 PR Newswire.
All rights reserved